Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UNICANCER
Age
18–60
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
histologically proven breast cancer
inflammatory breast cancer
no metastatic site
age \> or = 18 and \< or = 60
OMS score: 0, 1, 2
life expectancy \> or = 3 months
Normal (isotopic or ultrasonography) left ventricular ejection fraction
Normal haematological, liver, and kidney functions
patients who gave their written informed consent.
You may not be if
non inflammatory breast tumour with a cutaneous permeation nodule
presence of a metastatic site
medical history of a cancerous tumour except for carcinoma in situ of the uterine cervix, a basal cell skin cancer, or a breast carcinoma on the contralateral side
patients having already had a chemotherapy, a radiotherapy, or an hormone therapy for this breast tumour
medical history of congestive heart failure even medically controlled
medical history of myocardial infarction during the 6 months before the inclusion in the study
active infection or other severe underlying pathology which could possibly prevent the patient from receiving treatments
administration of another chemotherapy during the study
pregnant or breast feeding patients (the patients of childbearing age must be placed under efficient contraception)
patients whose social or psychological state does not allow to consider a correct adherence to the treatment and to the required medical follow-up
WHO score 3,4
unbalanced diabetes
polysorbate 80 allergy
Clareo Health | Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer
